Medicine Matters oncology

Overall survival is significantly longer with single-agent pembrolizumab than with platinum-based chemotherapy in patients with previously untreated, locally advanced or metastatic non-small-cell lung cancer that has programmed cell death ligand 1 expression levels of at least 1%, according to the KEYNOTE-042 results.

Treatment with high-dose proton pump inhibitors and aspirin, especially when taken together, could prevent the progression of Barrett’s esophagus, trial results suggest.

Results from the IMpower131 trial show that patients with stage IV squamous non-small-cell lung cancer derive a significant progression-free survival benefit from combining atezolizumab with chemotherapy.